A sexually active woman presents with vaginal discharge. According to the syndromic approach for management, which of the following drug regimens should be prescribed?
BCG vaccination is administered by which route?
What is the Category II treatment regimen for tuberculosis?
Japanese encephalitis is transmitted by which mosquito genus?
A 2-year duration in terms of leprosy refers to what?
The "EYE" strategy is developed for the elimination of which disease?
What is the standard first-line treatment regimen for Category 1 tuberculosis?
Who discovered the smallpox vaccine?
Which of the following is the drug of choice for chemoprophylaxis of cholera?
Which of the following is a live attenuated bacterial vaccine?
Explanation: ### Explanation **Concept:** The **Syndromic Approach** to Sexually Transmitted Infections (STIs) is a cornerstone of Community Medicine and NACO guidelines. It aims to treat the most likely causative organisms based on a group of symptoms (syndromes) rather than waiting for laboratory confirmation. **Why Option A is Correct:** A sexually active woman presenting with **vaginal discharge** is managed under the **Green Kit (Kit 2)** of the NACO guidelines. This kit targets three common causes of vaginal/cervical discharge: 1. **Bacterial Vaginosis:** Treated with **Metronidazole** (2g, single dose). 2. **Trichomoniasis:** Also treated with **Metronidazole**. 3. **Candidiasis (Yeast infection):** Treated with **Fluconazole** (150mg, single dose). 4. **Chlamydia/Gonorrhea:** Often co-managed with **Azithromycin** (1g, single dose) if cervical discharge/mucopurulent cervicitis is suspected (often integrated into the comprehensive management of vaginal discharge syndromes). **Why Other Options are Incorrect:** * **Option B & C:** These provide monotherapy. Treating only one organism (e.g., just bacteria or just Chlamydia) leads to treatment failure because vaginal discharge is frequently polymicrobial or caused by fungi. * **Option D:** While this covers Bacterial Vaginosis and Candidiasis, it misses the potential for concurrent Chlamydial infections, which are often asymptomatic but clinically significant in sexually active women. **High-Yield Clinical Pearls for NEET-PG:** * **Kit 1 (Grey):** Urethral discharge, Anorectal discharge, or Cervicitis (Azithromycin + Cefixime). * **Kit 2 (Green):** Vaginal discharge (Metronidazole + Fluconazole + Azithromycin). * **Kit 3 (White):** Non-herpetic Genital Ulcer (Penicillin + Azithromycin). * **Kit 6 (Yellow):** Lower Abdominal Pain/PID (Ceftriaxone + Metronidazole + Doxycycline). * **Key Goal:** The syndromic approach reduces the "lost to follow-up" rate by providing immediate, single-visit treatment.
Explanation: **Explanation:** **BCG (Bacillus Calmette-Guérin)** is a live attenuated vaccine derived from *Mycobacterium bovis*. The correct route of administration is **Intradermal (ID)**, typically given over the left deltoid muscle. **Why Intradermal is correct:** The intradermal route is essential for BCG because it ensures a slow, controlled release of the antigen into the lymphatic system. This specific route is necessary to trigger a **Delayed-Type Hypersensitivity (DTH) reaction**, which is essential for developing cell-mediated immunity against tuberculosis. Administering it deeper can lead to treatment failure or severe local complications. **Why other options are incorrect:** * **Subcutaneous/Intramuscular:** If BCG is accidentally injected into these deeper layers, it can lead to the formation of **cold abscesses** and regional lymphadenitis (suppurative lymphadenopathy) due to the live nature of the vaccine. * **Subdermal:** This is not a standard medical term for vaccine administration; the skin layers relevant to immunization are the epidermis, dermis (intradermal), and subcutaneous tissue. **High-Yield Clinical Pearls for NEET-PG:** * **Dose:** 0.05 ml for neonates (below 4 weeks) and 0.1 ml for infants above 4 weeks. * **Syringe:** A specialized **Tuberculin syringe** (Omega syringe) with a 26G needle is used. * **The "BCG Scar":** A characteristic wheal forms immediately, followed by a papule (2-3 weeks), which crusts and leaves a permanent tiny round scar (6-12 weeks). * **Diluent:** It is a freeze-dried vaccine reconstituted only with **Normal Saline**. Using Distilled Water can cause irritation, and Dextrose can lead to contamination. * **Stability:** Once reconstituted, it must be used within **4-6 hours** or discarded.
Explanation: In the context of the National Tuberculosis Elimination Program (NTEP), it is crucial to understand that the **Category II regimen** was historically used for "previously treated" cases (relapse, failure, or treatment after loss to follow-up). The correct answer is **D (All of the above)** because the Category II regimen is not a single phase, but a combination of three distinct phases that make up the total 8-month treatment duration: 1. **Intensive Phase (IP) - 2HRZES (Option A):** For the first 2 months, patients receive five drugs: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), and an injectable, Streptomycin (S). 2. **Extended Intensive Phase - 1HRZE (Option B):** After the initial 2 months, Streptomycin is stopped, and the patient continues with HRZE for 1 additional month. 3. **Continuation Phase (CP) - 5HRE (Option C):** For the final 5 months, the patient receives H, R, and E. **Why this is High-Yield for NEET-PG:** * **Historical Context:** Under the latest WHO and NTEP guidelines, **Category II has been phased out.** All patients (new and previously treated) are now started on the same 6-month daily regimen (2HRZE + 4HRE) unless Drug-Resistant TB (DR-TB) is suspected. * **The "S" Factor:** Category II was the only first-line regimen to include **Streptomycin**, an aminoglycoside. * **Drug-Resistant TB:** The shift away from Category II occurred because many "previously treated" cases actually had Multi-Drug Resistant TB (MDR-TB), and adding a single drug (Streptomycin) to a failing regimen promoted further resistance (the "Amplification Paradox"). **Clinical Pearl:** For the exam, if asked about the *current* protocol, remember: **Universal Drug Susceptibility Testing (UDST)** is now mandatory for all TB patients at the time of diagnosis to rule out Rifampicin resistance immediately.
Explanation: Japanese Encephalitis (JE) is a viral zoonosis caused by a Group B Arbovirus (Flavivirus). The primary vector for JE is the **Culex** mosquito, specifically the species ***Culex tritaeniorhynchus***. These mosquitoes are "exophilic" (rest outdoors) and "instar" breeders, typically found in stagnant water like irrigated rice fields. They are primarily zoophilic, meaning they prefer animal blood (pigs and water birds), which act as the natural reservoirs and amplifiers for the virus. **Analysis of Options:** * **Culex (Correct):** The principal vector for JE. They are nocturnal biters and are responsible for the rural distribution of the disease. * **Aedes:** Primarily the vector for **Dengue, Chikungunya, Zika, and Yellow Fever**. They are "day-biters" and breed in artificial containers (peri-domestic). * **Anopheles:** The definitive vector for **Malaria**. While some species can transmit filariasis, they are not involved in the JE transmission cycle. * **Mansonia:** The primary vector for **Brugian Filariasis** (*Brugia malayi*). They are unique because their larvae attach to the roots of aquatic plants (like *Pistia*) for respiration. **High-Yield Clinical Pearls for NEET-PG:** * **Reservoir/Amplifier Host:** The **Pig** is the most important amplifier host (the virus multiplies in pigs without causing disease). * **Dead-end Host:** **Humans** and **Horses** are incidental "dead-end" hosts because they do not develop sufficient viremia to infect subsequent mosquitoes. * **Sentinel Animals:** Pigs are used as sentinels to monitor the arrival of the virus in a community. * **Vaccination:** The most common vaccine used in the National Immunization Schedule (India) is the live attenuated **SA-14-14-2** strain.
Explanation: ### Explanation In the context of the National Leprosy Eradication Programme (NLEP), the duration of **post-treatment surveillance** (follow-up) is a critical component to monitor for relapse or late reactions. **1. Why Option C is Correct:** According to NLEP guidelines, once a patient completes the Multi-Drug Therapy (MDT) regimen, they enter a surveillance phase. For **Paucibacillary (PB) leprosy**, the surveillance period is **2 years**. During this time, patients are monitored to ensure there is no clinical recurrence of the disease. **2. Analysis of Incorrect Options:** * **Option A:** The treatment duration for PB leprosy is **6 months** (to be completed within a maximum of 9 months). * **Option B:** The treatment duration for Multibacillary (MB) leprosy is **12 months** (to be completed within a maximum of 18 months). * **Option D:** The post-treatment surveillance period for **MB leprosy** is **5 years**, reflecting the higher bacterial load and increased risk of late relapse compared to PB cases. **3. High-Yield Clinical Pearls for NEET-PG:** * **Classification:** PB leprosy involves 1–5 lesions and no nerve involvement (or only one nerve); MB leprosy involves >5 lesions or ≥2 nerve involvements. * **MDT Regimen (Adult MB):** Rifampicin (600mg monthly), Dapsone (100mg daily), and Clofazimine (300mg monthly + 50mg daily). * **MDT Regimen (Adult PB):** Rifampicin (600mg monthly) and Dapsone (100mg daily). * **Accompanied MDT:** A strategy where the full course of MDT is provided to the patient at the start to ensure treatment completion in difficult-to-reach areas. * **Release from Treatment (RFT):** A patient is "released from treatment" after completing the pulses, regardless of the persistence of skin patches, as these often take time to fade.
Explanation: **Explanation:** The **EYE strategy** stands for **"Eliminate Yellow Fever Epidemics."** It is a comprehensive global strategy launched in 2017 by the WHO, UNICEF, and Gavi, the Vaccine Alliance. The initiative was developed in response to the resurgence of Yellow Fever and aims to protect nearly 1 billion people in 40 high-risk countries (mainly in Africa and the Americas) by 2026. **The strategy relies on three strategic pillars:** 1. Protecting at-risk populations through vaccination. 2. Preventing international spread. 3. Containing outbreaks rapidly. **Analysis of Incorrect Options:** * **A. Yaws:** The global strategy for Yaws is the **"Morges Strategy,"** which focuses on eradication using oral Azithromycin. * **C. Leptospirosis:** There is no specific "EYE" strategy for Leptospirosis; control focuses on rodent control and sanitation. * **D. Zika virus:** While Zika is a flavivirus like Yellow Fever, its control falls under the **"Zika Strategic Response Framework,"** focusing on vector control and pregnancy monitoring. **High-Yield NEET-PG Pearls:** * **Yellow Fever Vaccine:** The **17D strain** is a live-attenuated vaccine. It provides lifelong immunity (as per WHO International Health Regulations since 2016). * **Validity:** The International Certificate of Vaccination becomes valid **10 days** after vaccination. * **Vector:** Primarily *Aedes aegypti* (Urban cycle) and *Haemagogus* species (Sylvan/Jungle cycle). * **India Status:** India is "Yellow Fever free" but remains receptive due to the presence of the *Aedes* vector. Strict quarantine rules apply to travelers from endemic zones.
Explanation: **Explanation:** Under the National Tuberculosis Elimination Program (NTEP), the standard treatment for all new cases of tuberculosis (formerly known as Category 1) follows a standardized short-course chemotherapy regimen. **1. Why Option A is Correct:** The standard regimen consists of an **Intensive Phase (IP)** of 2 months and a **Continuation Phase (CP)** of 4 months. * **Intensive Phase:** Uses four drugs—**H** (Isoniazid), **R** (Rifampicin), **Z** (Pyrazinamide), and **E** (Ethambutol)—to rapidly kill the actively multiplying bacilli and prevent the emergence of drug resistance. * **Continuation Phase:** Uses three drugs (**HRE**) for 4 months to eliminate semi-dormant bacilli and prevent relapse. (Note: In the current daily regimen, Ethambutol is included in the CP). **2. Analysis of Incorrect Options:** * **Option B (HRE):** This lacks Pyrazinamide. Pyrazinamide is essential in the first 2 months due to its unique ability to kill intracellular bacilli in acidic environments. * **Option C (ZRE):** This lacks Isoniazid (H), which is the most potent bactericidal drug against rapidly dividing organisms. * **Option D (HRZES):** This was the old "Category 2" regimen for previously treated cases. Streptomycin (S) is no longer used in standard first-line therapy to reduce the risk of ototoxicity and because the "Category 2" classification has been phased out in favor of drug-susceptibility testing (DST). **High-Yield Clinical Pearls for NEET-PG:** * **Dosage:** NTEP uses **daily fixed-dose combinations (FDC)** based on weight bands. * **Drug of Choice for Prophylaxis:** Isoniazid (6 months). * **Pyridoxine (Vit B6):** Always co-administer with Isoniazid to prevent peripheral neuropathy. * **Monitoring:** Sputum microscopy is done at the end of the IP (2 months) to assess conversion. * **Rifampicin:** The most important component; it causes orange-colored urine (benign side effect).
Explanation: **Explanation:** **Edward Jenner (Option A)** is the correct answer. In **1796**, Jenner observed that milkmaids who contracted cowpox (a milder disease) appeared immune to smallpox. He conducted a landmark experiment by inoculating a young boy, James Phipps, with material from a cowpox lesion and subsequently exposing him to smallpox, proving the concept of cross-immunity. This discovery laid the foundation for immunology and led to the eventual global eradication of smallpox in 1980. **Analysis of Incorrect Options:** * **Louis Pasteur (Option B):** Known as the "Father of Microbiology," he developed vaccines for **Rabies** and **Anthrax**. He also proposed the Germ Theory of Disease and invented pasteurization. * **Jonas Salk (Option C):** Developed the **Inactivated Polio Vaccine (IPV)** in 1955, which is administered via injection. * **Albert Sabin (Option D):** Developed the **Oral Polio Vaccine (OPV)** in 1961, which utilizes a live-attenuated virus. **High-Yield Clinical Pearls for NEET-PG:** * **Smallpox Eradication:** Smallpox is the only human infectious disease to be completely eradicated. The last naturally occurring case was reported in **Somalia (1977)**. * **Official Declaration:** The WHO declared the world free of smallpox on **May 8, 1980**. * **Bifurcated Needle:** This specialized tool was used for the "multiple puncture" technique in smallpox vaccination programs. * **Vaccinia Virus:** The smallpox vaccine used the live Vaccinia virus, not the Variola virus (which causes smallpox).
Explanation: **Explanation:** The drug of choice for the chemoprophylaxis of Cholera is **Tetracycline**. According to the World Health Organization (WHO) and standard public health guidelines, chemoprophylaxis is recommended only for close household contacts of a confirmed case to limit the secondary spread of *Vibrio cholerae*. * **Why Tetracycline is Correct:** Tetracycline (500 mg BD for 3 days in adults) is the traditional gold standard for prophylaxis. It effectively reduces the duration of stool excretion and the volume of diarrhea in contacts who may be incubating the disease. * **Why Doxycycline is Incorrect:** While Doxycycline is the **drug of choice for treatment** (as a single 300 mg dose) due to better compliance, it is generally considered a second-line or alternative option for mass prophylaxis compared to the established role of Tetracycline in public health protocols. * **Why Furazolidone and Cotrimoxazole are Incorrect:** These are alternative drugs used primarily in specific populations, such as pregnant women (Furazolidone) or children, where tetracyclines are contraindicated. They are not the primary choice for general chemoprophylaxis. **High-Yield Clinical Pearls for NEET-PG:** 1. **Treatment vs. Prophylaxis:** For **treatment** of Cholera, the DOC is a single dose of **Doxycycline**. For **prophylaxis**, the DOC is **Tetracycline**. 2. **Chemoprophylaxis Strategy:** Mass chemoprophylaxis of a whole community is **never recommended**; it is only for household contacts. 3. **Pregnant Women/Children:** Furazolidone is the preferred alternative when tetracyclines must be avoided. 4. **Public Health Priority:** The most important measure in cholera control is not antibiotics, but **rehydration (ORS/IV fluids)** and **sanitation (chlorination of water)**.
Explanation: **Explanation:** The classification of vaccines based on the nature of the antigen is a high-yield topic for NEET-PG. Vaccines are broadly categorized into Live Attenuated, Killed (Inactivated), Subunit/Fractional, and Toxoids. **1. Why BCG is the Correct Answer:** The **BCG (Bacillus Calmette-Guérin)** vaccine is a **Live Attenuated Bacterial** vaccine. It is derived from an attenuated (weakened) strain of *Mycobacterium bovis*. It is unique because most live vaccines used in the universal immunization program are viral; BCG is one of the few bacterial exceptions. **2. Analysis of Incorrect Options:** * **Oral Polio Vaccine (OPV):** This is a live attenuated vaccine, but it is **Viral**, not bacterial. (Sabin strain). * **Haemophilus influenzae type b (Hib):** This is a **Conjugate/Subunit** vaccine. It uses the capsular polysaccharide of the bacteria conjugated to a carrier protein to enhance immunogenicity. * **Whole-cell Pertussis (wP):** This is a **Killed (Inactivated) Bacterial** vaccine. It contains the entire *Bordetella pertussis* organism that has been inactivated by heat or chemicals. **3. NEET-PG High-Yield Pearls:** * **Live Bacterial Vaccines (Mnemonic: "B-Ty"):** **B**CG and Oral **Ty**phoid (Ty21a). * **BCG Administration:** Given intradermally (Left Deltoid) using an Omega/Tuberculin syringe. It produces a characteristic permanent scar. * **Diluent for BCG:** Normal Saline (NS). Reconstituted vaccine must be used within 4–6 hours to prevent contamination and loss of potency. * **Contraindication:** BCG should not be given to individuals with symptomatic HIV or generalized eczema.
Epidemiology of NCDs
Practice Questions
Cardiovascular Disease Prevention
Practice Questions
Diabetes Control Program
Practice Questions
Cancer Screening and Control
Practice Questions
Chronic Respiratory Diseases
Practice Questions
Mental Health Program
Practice Questions
Blindness Control Program
Practice Questions
Accident and Injury Prevention
Practice Questions
NCD Risk Factor Surveillance
Practice Questions
National Program for Prevention and Control of Cancer, Diabetes, CVD, and Stroke
Practice Questions
Oral Health Program
Practice Questions
Geriatric Health Issues
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free